642 related articles for article (PubMed ID: 32545494)
1. Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.
Bafna D; Ban F; Rennie PS; Singh K; Cherkasov A
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545494
[TBL] [Abstract][Full Text] [Related]
2. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
4. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
[TBL] [Abstract][Full Text] [Related]
5. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
7. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment.
Xia X; He J; Liu B; Shao Z; Xu Q; Hu T; Yu C; Liu X; Liao Y; Liu N; Huang H
Int J Biol Sci; 2020; 16(12):2192-2204. PubMed ID: 32549765
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Selective ERα/ERβ Ligands by Multi-pharmacophore Modeling and Virtual Screening.
Huang W; Wei W; Yang Y; Zhang T; Shen Z
Chem Pharm Bull (Tokyo); 2015; 63(10):780-91. PubMed ID: 26423034
[TBL] [Abstract][Full Text] [Related]
9.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
10. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
11. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a multi-target compound for estrogen receptor-positive (ER
Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
[TBL] [Abstract][Full Text] [Related]
15. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
16. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
17.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal estrogen receptor isoform-selective biphenyls.
Bhatnagar S; Soni A; Kaushik S; Rikhi M; Santhoshkumar TR; Jayaram B
Chem Biol Drug Des; 2018 Feb; 91(2):620-630. PubMed ID: 29052968
[TBL] [Abstract][Full Text] [Related]
20. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
